

# Phillipe Moreau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8033718/publications.pdf>

Version: 2024-02-01

588  
papers

49,805  
citations

1697

104  
h-index

1851

209  
g-index

598  
all docs

598  
docs citations

598  
times ranked

20499  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016, 17, e328-e346.	5.1	1,866
2	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
3	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	13.9	1,210
4	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. <i>American Journal of Hematology</i> , 2005, 79, 319-328.	2.0	1,179
5	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	13.9	1,144
6	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	13.9	1,139
7	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
8	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1782-1791.	13.9	1,022
9	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	13.9	924
10	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	13.9	861
11	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. <i>Blood</i> , 2007, 109, 3489-3495.	0.6	845
12	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. <i>Lancet Oncology, The</i> , 2011, 12, 431-440.	5.1	835
13	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	5.8	741
14	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology, The</i> , 2016, 17, 27-38.	5.1	723
15	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 1055-1066.	5.1	710
16	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	13.9	697
17	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1195-1206.	5.1	695
18	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686

#	ARTICLE	IF	CITATIONS
19	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	13.9	684
20	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 29-38.	6.3	665
21	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
22	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , 2006, 108, 3289-3294.	0.6	639
23	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
24	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2020, 21, 207-221.	5.1	544
25	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
26	Comparison of 200 mg/m <sup>2</sup> melphalan and 8 Gy total body irradiation plus 140 mg/m <sup>2</sup> melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrroupe Francophone du Myelome 9502 randomized trial. <i>Blood</i> , 2002, 99, 731-735.	0.6	531
27	Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4621-4629.	0.8	512
28	High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. <i>New England Journal of Medicine</i> , 2007, 357, 1083-1093.	13.9	473
29	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
30	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012, 120, 947-959.	0.6	438
31	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	6.3	435
32	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.	13.9	413
33	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. <i>Blood</i> , 2017, 130, 2401-2409.	0.6	403
34	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). <i>Journal of Clinical Oncology</i> , 2010, 28, 4630-4634.	0.8	383
35	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	0.6	377
36	Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3664-3670.	0.8	360

#	ARTICLE	IF	CITATIONS
37	Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. <i>Blood</i> , 2006, 107, 3474-3480.	0.6	344
38	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018, 132, 587-597.	0.6	335
39	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	0.8	330
40	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	0.8	330
41	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1327-1337.	5.1	320
42	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019, 33, 159-170.	3.3	313
43	Chromosome 13 abnormalities identified by FISH analysis and serum $\hat{I}^{22}$ -microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. <i>Blood</i> , 2001, 97, 1566-1571.	0.6	301
44	Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. <i>Blood</i> , 2002, 100, 1579-1583.	0.6	301
45	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018, 132, 2456-2464.	0.6	301
46	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	0.6	294
47	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	0.8	294
48	Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.	13.9	291
49	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
50	Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. <i>Blood</i> , 2011, 118, 5752-5758.	0.6	275
51	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	5.1	254
52	Prospective Evaluation of Magnetic Resonance Imaging and [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2911-2918.	0.8	247
53	Frontline therapy of multiple myeloma. <i>Blood</i> , 2015, 125, 3076-3084.	0.6	244
54	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. <i>Blood</i> , 2011, 118, 1239-1247.	0.6	243

#	ARTICLE	IF	CITATIONS
55	Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du My��lome. <i>Journal of Clinical Oncology</i> , 2014, 32, 2712-2717.	0.8	243
56	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 3279-3287.	0.8	238
57	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1630-1642.	5.1	237
58	Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. <i>Haematologica</i> , 2006, 91, 1498-505.	1.7	233
59	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. <i>Blood</i> , 2017, 130, 2392-2400.	0.6	229
60	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. <i>Blood</i> , 2016, 127, 2569-2574.	0.6	224
61	Anti-��B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 775-783.	0.8	222
62	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	0.6	216
63	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4767-4773.	3.2	212
64	Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-��refractory multiple myeloma: Intergroupe Francophone du My��lome 2009-02. <i>Blood</i> , 2013, 121, 1968-1975.	0.6	201
65	Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. <i>Journal of Clinical Oncology</i> , 2012, 30, 1949-1952.	0.8	198
66	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1563-1573.	6.3	188
67	Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , 2018, 103, 2088-2096.	1.7	187
68	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.	6.3	187
69	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2175-2182.	0.8	185
70	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016, 127, 681-695.	0.6	179
71	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	6.3	177
72	Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 42-54.	12.5	175

#	ARTICLE	IF	CITATIONS
73	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	13.9	173
74	CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. <i>Blood</i> , 2003, 102, 1070-1071.	0.6	170
75	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	2.8	170
76	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e370-e380.	2.2	170
77	Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. <i>Lancet Oncology</i> , 2018, 19, 953-964.	5.1	169
78	Genomic patterns of progression in smoldering multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3363.	5.8	163
79	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , 2020, 34, 1875-1884.	3.3	163
80	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 801-812.	5.1	162
81	Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). <i>Blood</i> , 2010, 115, 32-37.	0.6	152
82	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death. <i>Journal of Clinical Oncology</i> , 2014, 32, 2173-2180.	0.8	150
83	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	0.6	146
84	Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myélome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. <i>Journal of Clinical Oncology</i> , 2010, 28, 1209-1214.	0.8	144
85	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	0.6	144
86	Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. <i>Haematologica</i> , 2010, 95, 311-319.	1.7	142
87	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1582-1596.	5.1	141
88	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. <i>Lancet Haematology</i> , 2015, 2, e516-e527.	2.2	140
89	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, 32, 2604-2616.	3.3	137
90	Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection. <i>Genome Medicine</i> , 2016, 8, 49.	3.6	136

#	ARTICLE	IF	CITATIONS
91	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
92	PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. <i>Blood</i> , 2014, 124, 1626-1636.	0.6	134
93	How I treat extramedullary myeloma. <i>Blood</i> , 2016, 127, 971-976.	0.6	134
94	Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 1898-1906.	0.8	126
95	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. <i>Haematologica</i> , 2010, 95, 1973-1976.	1.7	124
96	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. <i>Leukemia</i> , 2020, 34, 224-233.	3.3	122
97	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	0.6	121
98	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , the, 2016, 3, e506-e515.	2.2	121
99	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <sc>Eloquent</sc> follow-up and <i>post-hoc</i> analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	1.2	120
100	Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. <i>Haematologica</i> , 2012, 97, 1925-1928.	1.7	119
101	Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. <i>Blood</i> , 2010, 116, 4777-4782.	0.6	118
102	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. <i>Blood</i> , 2011, 117, 2009-2011.	0.6	115
103	Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. <i>Haematologica</i> , 2008, 93, 1908-1911.	1.7	111
104	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1657-1665.	0.8	111
105	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	0.6	110
106	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 421-431.	0.6	110
107	Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. <i>Blood</i> , 2011, 117, 3041-3044.	0.6	109
108	Targeting Bcl-2 for the treatment of multiple myeloma. <i>Leukemia</i> , 2018, 32, 1899-1907.	3.3	109

#	ARTICLE	IF	CITATIONS
109	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
110	The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. <i>Nature Immunology</i> , 2021, 22, 769-780.	7.0	107
111	Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du My�lome Experience. <i>Journal of Clinical Oncology</i> , 2013, 31, 2806-2809.	0.8	103
112	Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1095-104.	1.4	102
113	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , 2015, 126, 391-391.	0.6	99
114	Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. <i>Blood</i> , 2006, 107, 397-403.	0.6	94
115	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019, 133, 1953-1963.	0.6	94
116	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e119-e130.	5.1	92
117	Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du My�lome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2125-2132.	0.8	91
118	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	1.9	90
119	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	0.6	90
120	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 91.	2.8	90
121	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 668-677.	0.6	87
122	Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2012, 51, 823-829.	1.6	86
123	Standardization of <sup>18</sup> F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	0.8	85
124	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1378-1390.	5.1	84
125	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. <i>Blood</i> , 2015, 125, 2095-2100.	0.6	82
126	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	3.3	81



#	ARTICLE	IF	CITATIONS
127	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	3.3	79
128	A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. <i>British Journal of Haematology</i> , 2000, 109, 661-664.	1.2	77
129	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 1815-1826.	1.3	75
130	FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. <i>Haematologica</i> , 2008, 93, 1269-1271.	1.7	70
131	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	0.8	70
132	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.	1.7	68
133	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
134	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
135	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
136	Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. <i>Blood Advances</i> , 2018, 2, 1633-1644.	2.5	66
137	How I treat myeloma with new agents. <i>Blood</i> , 2017, 130, 1507-1513.	0.6	65
138	Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 418-427.	2.0	64
139	Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. <i>Future Oncology</i> , 2020, 16, 4347-4358.	1.1	60
140	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. <i>Blood Cancer Journal</i> , 2018, 8, 95.	2.8	59
141	Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells. <i>Cancer Research</i> , 2012, 72, 4562-4573.	0.4	58
142	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	1.2	58
143	Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. <i>British Journal of Haematology</i> , 2019, 186, e117-e121.	1.2	58
144	Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets. <i>Frontiers in Immunology</i> , 2014, 5, 137.	2.2	57

#	ARTICLE	IF	CITATIONS
145	BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. <i>Blood</i> , 2018, 132, 2656-2669.	0.6	57
146	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , 2021, 39, 1139-1149.	0.8	57
147	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57
148	CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. <i>Leukemia Research</i> , 2008, 32, 379-382.	0.4	56
149	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 137.	6.9	56
150	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	3.3	55
151	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	3.3	54
152	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 416-427.	5.1	54
153	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	0.8	53
154	Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. <i>Haematologica</i> , 2004, 89, 547-51.	1.7	53
155	Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. <i>Blood Cancer Journal</i> , 2019, 9, 38.	2.8	52
156	Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection. <i>Cancer</i> , 1993, 72, 3223-3226.	2.0	51
157	The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies. <i>Seminars in Hematology</i> , 2012, 49, S33-S46.	1.8	50
158	Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 191-191.	0.6	50
159	A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. <i>Blood Cancer Journal</i> , 2021, 11, 89.	2.8	49
160	CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. <i>Haematologica</i> , 2005, 90, 706-7.	1.7	49
161	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. <i>Oncologist</i> , 2012, 17, 592-606.	1.9	48
162	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 737-748.	1.1	48

#	ARTICLE	IF	CITATIONS
163	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	1.2	48
164	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	1.7	48
165	del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. <i>Blood</i> , 2021, 137, 1192-1195.	0.6	48
166	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	0.6	48
167	Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01. <i>Blood</i> , 2007, 110, 75-75.	0.6	48
168	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 3100-3104.	0.6	47
169	Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. <i>British Journal of Haematology</i> , 2017, 179, 198-218.	1.2	47
170	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 522-530.e1.	0.2	47
171	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , 2021, 22, 142-154.	5.1	46
172	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
173	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	1.2	45
174	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	1.2	45
175	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, 1334-1339.	1.7	44
176	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). <i>Journal of Clinical Oncology</i> , 2021, 39, 3602-3612.	0.8	44
177	Multiple Myeloma: From Front-Line to Relapsed Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e504-e511.	1.8	43
178	Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). <i>Haematologica</i> , 2017, 102, e112-e114.	1.7	43
179	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	0.6	43
180	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	3.3	43

#	ARTICLE	IF	CITATIONS
181	Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE <sup>®</sup> ) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study. <i>Blood</i> , 2018, 132, 1010-1010.	0.6	42
182	Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. <i>Blood</i> , 2019, 134, 692-692.	0.6	42
183	Patient-reported health-related quality of life from the phase III TOURMALINE <sup>®</sup> MM1 study of ixazomib+lenalidomide+dexamethasone versus placebo+lenalidomide+dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	2.0	41
184	Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 5-6.	0.6	41
185	How to Manage Neutropenia in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 5-11.	0.2	40
186	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 519-530.	0.2	40
187	Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8001-8001.	0.8	40
188	Phase 2 study of tabalumab, a human anti-BAFF cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. <i>British Journal of Haematology</i> , 2017, 176, 783-795.	1.2	39
189	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus) Tj ETQq1 1 0.784314 rgBT /Ove (Pts) Ineligible For Stem Cell Transplantation (SCT). <i>Blood</i> , 2013, 122, 2-2.	0.6	39
190	Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8010-8010.	0.8	39
191	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 4350-4355.	3.2	38
192	How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 153-170.	2.0	37
193	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	0.6	37
194	Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergrupe Francophone Du Myelome (IFM) Krd Phase II Study. <i>Blood</i> , 2016, 128, 1142-1142.	0.6	36
195	Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. <i>Haematologica</i> , 2014, 99, 1236-1238.	1.7	35
196	Daratumumab for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 887-893.	1.4	35
197	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1005-1015.	3.3	35
198	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	3.3	35

#	ARTICLE	IF	CITATIONS
199	Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 1888-1888.	0.6	35
200	Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. <i>Haematologica</i> , 2015, 100, e56-e59.	1.7	34
201	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	4.9	34
202	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	1.2	33
203	Multiple myeloma—translation of trial results into reality. <i>Lancet, The</i> , 2016, 388, 111-113.	6.3	32
204	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 23.	2.8	32
205	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.	2.0	32
206	A pilot study of 220 mg/m <sup>2</sup> melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. <i>British Journal of Haematology</i> , 1996, 95, 527-530.	1.2	31
207	Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. <i>Haematologica</i> , 2015, 100, e207-e210.	1.7	31
208	Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes. <i>Cell Death and Disease</i> , 2020, 11, 316.	2.7	31
209	Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8055-TPS8055.	0.8	31
210	Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 2161-2163.	0.6	30
211	Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. <i>Annals of Hematology</i> , 2019, 98, 1435-1440.	0.8	30
212	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). <i>Blood</i> , 2018, 132, LBA-2-LBA-2.	0.6	30
213	Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux. <i>Blood</i> , 2017, 130, 739-739.	0.6	30
214	Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. <i>Oncotarget</i> , 2015, 6, 26922-26934.	0.8	29
215	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	0.6	29
216	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 121, 74-89.	2.0	28

#	ARTICLE	IF	CITATIONS
217	Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1866-1866.	0.6	28
218	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. <i>Blood</i> , 2016, 128, 246-246.	0.6	28
219	Ancestim (r-metHuSCF) Plus Filgrastim for the Mobilization and Collection of Peripheral Blood Progenitor Cells for Autologous Transplant after Failure of Prior Mobilization: The French Experience of Compassionate Use.. <i>Blood</i> , 2007, 110, 3281-3281.	0.6	28
220	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	0.6	27
221	An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 176-176.	0.6	27
222	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. <i>Blood</i> , 2016, 128, 488-488.	0.6	27
223	A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2012, 18, 5043-5050.	3.2	26
224	<sc>BH</sc>3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 684-688.	1.2	26
225	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. <i>Haematologica</i> , 2014, 99, 1486-1491.	1.7	25
226	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.	1.1	25
227	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017, 117, 185-191.	3.1	25
228	<p>Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patientsâ€™™ selection and perspective</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5813-5822.	1.0	25
229	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. <i>Blood</i> , 2019, 134, 142-142.	0.6	25
230	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 35-48.	1.3	24
231	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017, 10, 229-237.	1.0	24
232	Safety and antibody response after one and/or two doses of BNT162b2 Antiâ€™SARSâ€™CoVâ€™2 mRNA vaccine in patients treated by CAR T cells therapy. <i>British Journal of Haematology</i> , 2022, 196, 360-362.	1.2	24
233	Quisinosat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1546-1559.	0.6	23
234	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 445.	1.8	23

#	ARTICLE	IF	CITATIONS
235	Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m <sup>2</sup> vs. twice-weekly 27 mg/m <sup>2</sup> carfilzomib (randomized A.R.R.O.W. study). <i>Leukemia</i> , 2019, 33, 2934-2946.	3.3	23
236	Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, e63-e67.	1.7	22
237	Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in multiple myeloma cells couple ER stress to mitochondrial apoptosis. <i>Cancer Letters</i> , 2016, 383, 204-211.	3.2	22
238	Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. <i>Haematologica</i> , 2021, 106, 2257-2260.	1.7	22
239	Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. <i>Blood</i> , 2021, 138, 113-121.	0.6	22
240	Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. <i>Blood</i> , 2018, 132, 595-595.	0.6	22
241	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , 2015, 126, 28-28.	0.6	22
242	Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 8509-8509.	0.8	22
243	Stem-cell transplantation in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 603-618.	0.7	21
244	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
245	Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	21
246	The emerging role of carfilzomib combination therapy in the management of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 265-290.	1.0	20
247	Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. <i>Leukemia and Lymphoma</i> , 2014, 55, 2165-2173.	0.6	20
248	Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e874-e883.	2.2	20
249	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	0.6	20
250	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 395-395.	0.6	20
251	Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO). <i>Blood</i> , 2016, 128, 1149-1149.	0.6	20
252	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 975-975.	0.6	20

#	ARTICLE	IF	CITATIONS
253	Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.. Journal of Clinical Oncology, 2022, 40, 8013-8013.	0.8	20
254	RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway. BMC Cancer, 2014, 14, 437.	1.1	19
255	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica, 2016, 101, 872-878.	1.7	19
256	Overall Survival in Spine Myeloma Metastases: Difficulties in Predicting With Prognostic Scores. Spine, 2017, 42, 400-406.	1.0	19
257	MRD in multiple myeloma: more questions than answers?. Blood Cancer Journal, 2017, 7, 639.	2.8	19
258	New developments in the management of relapsed/refractory multiple myeloma &ndash; the role of ixazomib. Journal of Blood Medicine, 2017, Volume 8, 107-121.	0.7	19
259	Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma.. Blood, 2007, 110, 1166-1166.	0.6	19
260	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica, 2022, 107, 2408-2417.	1.7	19
261	Cereblon expression in multiple myeloma: not ready for prime time. British Journal of Haematology, 2013, 163, 282-284.	1.2	18
262	Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. Expert Review of Hematology, 2017, 10, 207-215.	1.0	18
263	Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014&O4 (Etoile du Nord) trial. British Journal of Haematology, 2019, 187, 319-327.	1.2	18
264	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 2019, 104, 2358-2360.	1.7	18
265	Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2020, 61, 1323-1333.	0.6	18
266	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. Blood, 2009, 114, 2878-2878.	0.6	18
267	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. Cancers, 2020, 12, 2532.	1.7	17
268	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia, 2020, 34, 3019-3027.	3.3	17
269	Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3245-3245.	0.6	17
270	Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor. Blood, 2018, 132, 3272-3272.	0.6	17



#	ARTICLE	IF	CITATIONS
271	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018, 132, 598-598.	0.6	17
272	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. <i>Oncotarget</i> , 2018, 9, 33528-33535.	0.8	17
273	Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. <i>Haematologica</i> , 2014, 99, e33-e34.	1.7	16
274	Complete Donor T Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced-Intensity Conditioning Regimen Allogeneic Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 180-184.	2.0	16
275	The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. <i>Advances in Therapy</i> , 2016, 33, 1896-1920.	1.3	16
276	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <sc>PANORAMA</sc> 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	1.2	16
277	Safety of ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 973-980.	1.0	16
278	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020, 10, 35.	2.8	16
279	Once- versus twice-weekly (70 mg/m <sup>2</sup> vs twice-weekly (56 mg/m <sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION trials. <i>Cancer Medicine</i> , 2020, 9, 2989-2996.	1.3	16
280	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	2.0	16
281	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. <i>Blood</i> , 2015, 126, 3038-3038.	0.6	16
282	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , 2016, 128, 3307-3307.	0.6	16
283	Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myélome (IFM). <i>Blood</i> , 2016, 128, 674-674.	0.6	16
284	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. <i>Haematologica</i> , 2022, 107, 1397-1409.	1.7	16
285	Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 84-84.	0.6	16
286	Supporting the Return to Work of Breast Cancer Survivors: From a Theoretical to a Clinical Perspective. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5124.	1.2	16
287	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. <i>Blood</i> , 2022, 139, 2747-2757.	0.6	16
288	A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2013-2017.	0.6	15

#	ARTICLE	IF	CITATIONS
289	A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. <i>British Journal of Haematology</i> , 2018, 183, 736-746.	1.2	15
290	Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia Research</i> , 2019, 83, 106172.	0.4	15
291	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	2.0	15
292	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. <i>Blood</i> , 2020, 136, 7-8.	0.6	15
293	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.	0.6	15
294	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. <i>Blood</i> , 2015, 126, 730-730.	0.6	15
295	ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8508-8508.	0.8	15
296	“Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?” <i>Leukemia Research</i> , 2012, 36, 677-681.	0.4	14
297	Initial treatment of transplant-eligible patients in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 43-53.	1.0	14
298	Oral therapy for multiple myeloma: ixazomib arriving soon. <i>Blood</i> , 2014, 124, 986-987.	0.6	14
299	Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study. <i>Blood</i> , 2018, 132, 3243-3243.	0.6	14
300	Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study. <i>Blood</i> , 2010, 116, 624-624.	0.6	14
301	Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. <i>Blood</i> , 2012, 120, LBA-6-LBA-6.	0.6	14
302	Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 3187-3187.	0.6	14
303	ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS8113-TPS8113.	0.8	14
304	Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1318-1320.	0.6	13
305	All transplantation-eligible patients with myeloma should receive ASCT in first response. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 250-254.	0.9	13
306	The role of SLAMF7 in multiple myeloma: impact on therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 67-75.	1.3	13

#	ARTICLE	IF	CITATIONS
307	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5406.	1.8	13
308	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020, 10, 111.	2.8	13
309	Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 965-973.	1.9	13
310	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019, 134, 3140-3140.	0.6	13
311	Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program. <i>Blood</i> , 2011, 118, 1872-1872.	0.6	13
312	Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux. <i>Blood</i> , 2016, 128, 489-489.	0.6	13
313	Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8015-8015.	0.8	13
314	A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS8554-TPS8554.	0.8	13
315	Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults. <i>Blood</i> , 2014, 124, 2479-2479.	0.6	13
316	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. <i>Journal of Clinical Oncology</i> , 2022, 40, 3132-3150.	0.8	13
317	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018, 32, 2032-2036.	3.3	12
318	Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. <i>Trials. International Journal of Hematology</i> , 2019, 110, 466-473.	0.7	12
319	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	1.2	12
320	Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8004-8004.	0.8	12
321	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. <i>American Journal of Hematology</i> , 2021, 96, 896-900.	2.0	12
322	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1.. <i>Blood</i> , 2011, 118, 3976-3976.	0.6	12
323	Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8542-8542.	0.8	12
324	Frontline treatment of multiple myeloma in elderly patients. <i>Blood Reviews</i> , 2008, 22, 303-309.	2.8	11

#	ARTICLE	IF	CITATIONS
325	Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. <i>Leukemia and Lymphoma</i> , 2019, 60, 462-470.	0.6	11
326	The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. <i>Leukemia</i> , 2020, 34, 167-179.	3.3	11
327	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	0.6	11
328	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	6.9	11
329	Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8017-8017.	0.8	11
330	Improved survival in multiple myeloma during the 2005â€“2009 and 2010â€“2014 periods. <i>Leukemia</i> , 2021, 35, 3600-3603.	3.3	11
331	Induction with VelcadeÂ®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 957-957.	0.6	11
332	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase I Preliminary Results. <i>Blood</i> , 2015, 126, 4219-4219.	0.6	11
333	Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 1162-1162.	0.6	11
334	Final Analysis of Overall Survival from the First Trial. <i>Blood</i> , 2016, 128, 241-241.	0.6	11
335	Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8002-8002.	0.8	11
336	Patients Under 50 Years of Age Do Not Present Specific Prognostic Characteristics: An IFM Study in 1897 Patients Under 65 Years of Age.. <i>Blood</i> , 2009, 114, 2837-2837.	0.6	11
337	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
338	Early Intensive Therapy with Autotransplantation for High-Risk Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 1993, 12, 51-58.	0.6	10
339	Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. <i>Expert Review of Hematology</i> , 2021, 14, 1099-1114.	1.0	10
340	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: <sc>ICARIAâ€“MM</sc> subgroup analysis. <i>American Journal of Hematology</i> , 2021, 96, E423-E427.	2.0	10
341	Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018, 132, 1996-1996.	0.6	10
342	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2018, 132, 1994-1994.	0.6	10

#	ARTICLE	IF	CITATIONS
343	Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.. Blood, 2009, 114, 1818-1818.	0.6	10
344	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 408-408.	0.6	10
345	Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8009-8009.	0.8	10
346	Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2018, 36, 8040-8040.	0.8	10
347	Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials.. Journal of Clinical Oncology, 2020, 38, 8540-8540.	0.8	10
348	Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. Haematologica, 2021, 106, 701-707.	1.7	10
349	Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2. Blood, 2021, 138, 82-82.	0.6	10
350	B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 279.e1-279.e4.	0.6	10
351	Elotuzumab for the treatment of multiple myeloma. Future Oncology, 2014, 10, 949-956.	1.1	9
352	Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Leukemia and Lymphoma, 2016, 57, 2839-2847.	0.6	9
353	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. Clinical Epigenetics, 2020, 12, 163.	1.8	9
354	Newly Diagnosed Myeloma in 2020. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e144-e158.	1.8	9
355	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. Immunotherapy, 2021, 13, 143-154.	1.0	9
356	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood, 2018, 132, 301-301.	0.6	9
357	A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma. Blood, 2010, 116, 312-312.	0.6	9
358	Adjuvant Chemotherapy in the Treatment of Solitary Bone Plasmacytoma. Blood, 2016, 128, 4514-4514.	0.6	9
359	Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.. Journal of Clinical Oncology, 2019, 37, 8017-8017.	0.8	9
360	Ciltacabtagene Autoleucl for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study. Blood, 2021, 138, 550-550.	0.6	9

#	ARTICLE	IF	CITATIONS
361	Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2012, 36, S13-S18.	0.4	8
362	Pomalidomide in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2016, 12, 1975-1983.	1.1	8
363	FLT3 ligand plasma levels in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, e240-e243.	1.7	8
364	ImmunoPET in Multiple Myelomaâ€”What? So What? Now What?. <i>Cancers</i> , 2020, 12, 1467.	1.7	8
365	câ€MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomideâ€dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	1.1	8
366	Imaging of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Cancers</i> , 2020, 12, 486.	1.7	8
367	Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. <i>Bone Marrow Transplantation</i> , 2021, 56, 395-399.	1.3	8
368	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	1.1	8
369	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomideâ€pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
370	First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 925-925.	0.6	8
371	A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials.. <i>Blood</i> , 2005, 106, 622-622.	0.6	8
372	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 303-303.	0.6	8
373	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2014, 124, 3359-3359.	0.6	8
374	Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8018-8018.	0.8	8
375	Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8002-8002.	0.8	8
376	Initial Treatment of Transplant Candidates With Multiple Myeloma. <i>Seminars in Oncology</i> , 2013, 40, 585-591.	0.8	7
377	Ixazomib in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2018, 14, 2013-2020.	1.1	7
378	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. <i>Annals of Hematology</i> , 2020, 99, 1341-1350.	0.8	7

#	ARTICLE	IF	CITATIONS
379	Clinical benefit of ixazomib plus lenalidomide+dexamethasone in myeloma patients with non-canonical NF- $\kappa$ B pathway activation. <i>European Journal of Haematology</i> , 2020, 105, 274-285.	1.1	7
380	No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. <i>British Journal of Haematology</i> , 2021, 194, 635-638.	1.2	7
381	High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02. <i>Blood</i> , 2011, 118, 812-812.	0.6	7
382	Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab. <i>Blood</i> , 2016, 128, 2063-2063.	0.6	7
383	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8527-8527.	0.8	7
384	Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8038-8038.	0.8	7
385	MIDAM Regimen (Mylotarg + Intermediate Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients.. <i>Blood</i> , 2006, 108, 1957-1957.	0.6	7
386	Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
387	Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8007-8007.	0.8	7
388	Extramedullary multiple myeloma: extraosseous relapse is extra bad news, but why?. <i>Leukemia and Lymphoma</i> , 2013, 54, 1349-1350.	0.6	6
389	Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 829-838.	0.9	6
390	Bortezomib+thalidomide+dexamethasone versus bortezomib+cyclophosphamide+dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2015, 168, 605-606.	1.2	6
391	Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1044-1047.	1.3	6
392	Carfilzomib+dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1364-1374.	0.6	6
393	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 906-911.	2.0	6
394	FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. <i>Cancers</i> , 2020, 12, 1384.	1.7	6
395	LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving $\geq 3$ prior lines of therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8041-8041.	0.8	6
396	Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study. <i>British Journal of Haematology</i> , 2021, 194, e48-e51.	1.2	6

#	ARTICLE	IF	CITATIONS
397	A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 642-648.	1.3	6
398	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. <i>Blood</i> , 2009, 114, 743-743.	0.6	6
399	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. <i>Blood</i> , 2010, 116, 986-986.	0.6	6
400	Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial. <i>Blood</i> , 2016, 128, 2138-2138.	0.6	6
401	Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8003-8003.	0.8	6
402	Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial. <i>American Journal of Hematology</i> , 2022, 97, 481-490.	2.0	6
403	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. <i>American Journal of Hematology</i> , 2023, 98, .	2.0	6
404	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. <i>Hematological Oncology</i> , 2022, 40, 1020-1029.	0.8	6
405	Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 885-890.	1.1	5
406	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?. <i>European Journal of Haematology</i> , 2017, 99, 60-69.	1.1	5
407	The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. <i>BMC Cancer</i> , 2019, 19, 855.	1.1	5
408	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. <i>Leukemia</i> , 2021, 35, 1732-1744.	3.3	5
409	Monoclonal antibodies as an addition to current myeloma therapy strategies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 33-43.	1.1	5
410	Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2254-2260.	1.3	5
411	Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimism Trial. <i>Blood</i> , 2018, 132, 3278-3278.	0.6	5
412	Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRd Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03). <i>Blood</i> , 2019, 134, 3159-3159.	0.6	5
413	Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. <i>IFM 2009-02. Blood</i> , 2010, 116, 859-859.	0.6	5
414	Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 3026-3026.	0.6	5



#	ARTICLE	IF	CITATIONS
415	CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy. <i>Blood</i> , 2016, 128, 5268-5268.	0.6	5
416	ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)â€”Identifying responders by subset analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8037-8037.	0.8	5
417	Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8028-8028.	0.8	5
418	High Resolution Genome-Wide Analyses Revealed That Bortezomib Selects a Prediagnosis Clone In Relapsed Patients with Multiple Myeloma. <i>Blood</i> , 2010, 116, 2960-2960.	0.6	5
419	Meta-analysis of ciltacabtagene autoleucel versus physicianâ€™s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. <i>Current Medical Research and Opinion</i> , 2022, 38, 1759-1767.	0.9	5
420	Early Intensive Therapy with Autologous Stem Cell Transplantation in High-Risk Hodgkin's Disease: Long-Term Follow-Up in 35 Cases. <i>Leukemia and Lymphoma</i> , 1998, 30, 313-324.	0.6	4
421	Global Approaches in Myeloma: Critical Trials That May Change Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 656-661.	1.8	4
422	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1793-1804.	0.8	4
423	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta Oncologica</i> , 2021, 60, 466-474.	0.8	4
424	The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial. <i>Blood</i> , 2018, 132, 716-716.	0.6	4
425	Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group. <i>Blood</i> , 2016, 128, 4612-4612.	0.6	4
426	Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du MyÃ©lome (IFM) 2009-01 protocol.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8014-8014.	0.8	4
427	Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8513-8513.	0.8	4
428	Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8025-8025.	0.8	4
429	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8035-8035.	0.8	4
430	Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8538-8538.	0.8	4
431	High Grade Non-Hodgkinâ€™s Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis.. <i>Blood</i> , 2006, 108, 2045-2045.	0.6	4
432	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1770-1770.	0.6	4

#	ARTICLE	IF	CITATIONS
433	Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 817-817.	0.6	4
434	Molecular Signature of <sup>18</sup> F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1008-1013.	2.8	4
435	Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant. <i>EJHaem</i> , 2022, , .	0.4	4
436	Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8035-8035.	0.8	4
437	Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8052-8052.	0.8	4
438	Role of Bone Marrow Transplantation in the Disease Pathway of Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 163-169.	2.3	3
439	Advances in biology and therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 628-630.	12.5	3
440	Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. <i>Scientific Reports</i> , 2020, 10, 15399.	1.6	3
441	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020, 136, 4-6.	0.6	3
442	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015, 126, 4201-4201.	0.6	3
443	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 4225-4225.	0.6	3
444	A Phase I/II Study of Vaccination By Autologous Leukemic Apoptotic Corpse Pulsed Dendritic Cells for Elderly Acute Myeloid Leukemia Patients in First or Second Complete Remission (LAM DC trial). <i>Blood</i> , 2016, 128, 2821-2821.	0.6	3
445	Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8032-8032.	0.8	3
446	TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2745-2745.	0.6	3
447	Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts. <i>Blood</i> , 2020, 136, 28-28.	0.6	3
448	Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4-LBA4.	0.8	3
449	New Data on Subcutaneous Bortezomib. <i>Acta Haematologica</i> , 2015, 133, 26-28.	0.7	2
450	RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. <i>EJHaem</i> , 2020, 1, 318-322.	0.4	2

#	ARTICLE	IF	CITATIONS
451	Paving the way to precision medicine in multiple myeloma. Expert Review of Hematology, 2021, 14, 323-327.	1.0	2
452	Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma. Blood, 2019, 134, 1799-1799.	0.6	2
453	High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial. Blood, 2010, 116, 1758-1758.	0.6	2
454	Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study. Blood, 2010, 116, 1936-1936.	0.6	2
455	Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics. Blood, 2011, 118, 1863-1863.	0.6	2
456	Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial. Blood, 2013, 122, 2939-2939.	0.6	2
457	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (&gt; 65 Years of Age). Blood, 2013, 122, 3198-3198.	0.6	2
458	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 686-686.	0.6	2
459	First Large Prospective Study For Patients With Primary Plasma Cell Leukemia: Bortezomib-Doxorubicine-Dexamethasone/Bortezomib-Cyclophosphamide-Dexamethasone Regimens As Induction Before Stem Cell Transplantation Followed By Consolidation With Lenalidomide-Bortezomib-Dex Or Allograft. (a study of the IFM group). Blood, 2013, 122, 761-761.	0.6	2
460	Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM) Tj ETQq0 0.0 rgBT /Oyerlock 10	0.6	2
461	Multiple Myeloma (MM): Impact of Immunoglobulin Isotype on the Speed of Response. Blood, 2015, 126, 4191-4191.	0.6	2
462	A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients. Blood, 2016, 128, 238-238.	0.6	2
463	A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8020-8020.	0.8	2
464	MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2013, 31, 8510-8510.	0.8	2
465	The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.. Journal of Clinical Oncology, 2014, 32, TPS8625-TPS8625.	0.8	2
466	Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1.. Journal of Clinical Oncology, 2016, 34, 8036-8036.	0.8	2
467	Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.. Journal of Clinical Oncology, 2016, 34, 8039-8039.	0.8	2
468	Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.. Journal of Clinical Oncology, 2019, 37, 8042-8042.	0.8	2

#	ARTICLE	IF	CITATIONS
469	Light Chain Escape in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1881-1881.	0.6	2
470	Meta-Analysis of Ciltacabtagene Autoleucl versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1676-1676.	0.6	2
471	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210884.	1.1	2
472	Treatment emergent peripheral neuropathy in the CASSIOPEIA trial. <i>Haematologica</i> , 2022, 107, 1726-1730.	1.7	2
473	Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. <i>International Journal of Hematology</i> , 2022, 116, 553-562.	0.7	2
474	Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, e20028-e20028.	0.8	2
475	Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8033-8033.	0.8	2
476	Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8030-8030.	0.8	2
477	VI. Autologous stem cell transplantation and maintenance therapy. <i>Hematological Oncology</i> , 2013, 31, 42-46.	0.8	1
478	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018, , 73-96.	0.2	1
479	Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 40.	1.8	1
480	FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. <i>Cytokine</i> , 2019, 120, 85-87.	1.4	1
481	18F-FDG PET/CT in multiple myeloma: critical insights and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1048-1050.	3.3	1
482	Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2021, 17, 993-998.	1.1	1
483	Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply. <i>Lancet, The</i> , 2021, 397, 1621-1623.	6.3	1
484	Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8046-8046.	0.8	1
485	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8034-8034.	0.8	1
486	Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 190-190.	0.6	1

#	ARTICLE	IF	CITATIONS
487	Association between Patient Profile and Outcomes of Best Responders to Carfilzomib: A Post-Hoc Sub-Group Analysis of Aspire and Endeavor. <i>Blood</i> , 2018, 132, 3299-3299.	0.6	1
488	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , 2018, 132, 1960-1960.	0.6	1
489	Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines. <i>Blood</i> , 2018, 132, 3244-3244.	0.6	1
490	Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM). <i>Blood</i> , 2019, 134, 4740-4740.	0.6	1
491	Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1876-1876.	0.6	1
492	Peripheral Neuropathy in the Cassiopeia Study. <i>Blood</i> , 2020, 136, 48-48.	0.6	1
493	Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs?. <i>Blood</i> , 2009, 114, 3869-3869.	0.6	1
494	An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival. <i>Blood</i> , 2015, 126, 2093-2093.	0.6	1
495	Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial. <i>Blood</i> , 2016, 128, 1096-1096.	0.6	1
496	The Oncolytic Measles Virus Preferentially Infects p53 Abnormal Myeloma Cells. <i>Blood</i> , 2016, 128, 310-310.	0.6	1
497	A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications. <i>Blood</i> , 2016, 128, 356-356.	0.6	1
498	Free Light Chain Escape in Multiple Myeloma : an Exceptional Phenomenon. <i>Blood</i> , 2016, 128, 4428-4428.	0.6	1
499	Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8583-8583.	0.8	1
500	Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8060-TPS8060.	0.8	1
501	Corticosteroid tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8537-8537.	0.8	1
502	Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group.. <i>Blood</i> , 2006, 108, 3577-3577.	0.6	1
503	Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in Myeloma in Vitro and In Vivo.. <i>Blood</i> , 2009, 114, 833-833.	0.6	1
504	Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation. <i>Blood</i> , 2010, 116, 3043-3043.	0.6	1

#	ARTICLE	IF	CITATIONS
505	Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4770-4770.	0.6	1
506	Larger Number of Invariant Natural Killer T-Cells in Allogeneic Peripheral Blood Stem Cell Grafts Is Associated with Improved Graft-Versus-Host Disease-Free, Progression-Free Survival after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 514-514.	0.6	1
507	No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2015, 126, 2520-2520.	0.6	1
508	Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8000-8000.	0.8	1
509	Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimism Trial By Patient Age and Prior Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3120-3120.	0.6	1
510	Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 1836-1836.	0.6	1
511	Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4348-4348.	0.6	1
512	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. <i>Blood</i> , 2019, 134, 5549-5549.	0.6	1
513	Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells. <i>Blood</i> , 2019, 134, 3109-3109.	0.6	1
514	Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3911-3911.	0.6	1
515	Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study. <i>Blood</i> , 2021, 138, 2747-2747.	0.6	1
516	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy. <i>Blood</i> , 2021, 138, 3057-3057.	0.6	1
517	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). <i>Blood</i> , 2021, 138, 1634-1634.	0.6	1
518	Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study. <i>Blood</i> , 2021, 138, 1667-1667.	0.6	1
519	A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft. <i>Blood</i> , 2021, 138, 1812-1812.	0.6	1
520	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. <i>Blood</i> , 2021, 138, 1646-1646.	0.6	1
521	Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone. <i>Blood</i> , 2021, 138, 1633-1633.	0.6	1
522	Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study. <i>Blood</i> , 2020, 136, 40-41.	0.6	1

#	ARTICLE	IF	CITATIONS
523	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	1.2	1
524	Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2022, 40, 8016-8016.	0.8	1
525	Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.. Journal of Clinical Oncology, 2022, 40, 8044-8044.	0.8	1
526	Subgroup analyses in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.. Journal of Clinical Oncology, 2022, 40, 8031-8031.	0.8	1
527	RIC alloSCT in MM: a long way to go. Blood, 2011, 118, 2378-2379.	0.6	0
528	Reply to A. Gratwohl. Journal of Clinical Oncology, 2011, 29, e484-e484.	0.8	0
529	Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. EJHaem, 2020, 1, 481-488.	0.4	0
530	Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (Dâ€œVTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching. EJHaem, 2021, 2, 66-80.	0.4	0
531	In search of the optimal proteasome inhibitor. How, when and for whom?. Haematologica, 2021, 106, 2539-2541.	1.7	0
532	Isatuximab plus carfilzomib and dexamethasone in east Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, e20015-e20015.	0.8	0
533	Reply to G. R. Mohyuddin et al and A. Garfall et al. Journal of Clinical Oncology, 2021, , JCO2102081.	0.8	0
534	Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimen (RIC) for Adult Patients with AML: Same Results in Secondary and De Novo AML.. Blood, 2006, 108, 3015-3015.	0.6	0
535	High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients.. Blood, 2007, 110, 657-657.	0.6	0
536	Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. Blood, 2009, 114, 1187-1187.	0.6	0
537	Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies.. Blood, 2009, 114, 1142-1142.	0.6	0
538	Lenalidomide in Combination with Melphalan and Dexamethasone in Patients with Newly-Diagnosed Light-Chain (AL)-Amyloidosis: a Multicenter Phase I/II Dose Escalation Study.. Blood, 2009, 114, 427-427.	0.6	0
539	New Strategy for Allogeneic Peripheral Blood Stem Cell Transplantation After Reduced Intensity Conditioning in Multiple Myeloma: Interim Analysis of the IFM2005-03 Study.. Blood, 2009, 114, 4321-4321.	0.6	0
540	Fludarabine, Low Dose Busulfan and Antithymocyte Globulin for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2009, 114, 3341-3341.	0.6	0

#	ARTICLE	IF	CITATIONS
541	A Randomized Phase II Study Evaluating the Efficacy, Safety and Cost-Effectiveness of Pegfilgrastim and Filgrastim After High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Lymphoma and Myeloma (PALM Study).. Blood, 2010, 116, 3479-3479.	0.6	0
542	Chronic Viral Infection, Virus-Specific Monoclonal Immunoglobulin, and Development of Plasma Cell Malignancy. Blood, 2011, 118, 2875-2875.	0.6	0
543	ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).. Journal of Clinical Oncology, 2012, 30, TPS8112-TPS8112.	0.8	0
544	A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).. Journal of Clinical Oncology, 2012, 30, TPS8114-TPS8114.	0.8	0
545	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.. Journal of Clinical Oncology, 2013, 31, 8528-8528.	0.8	0
546	Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial. Blood, 2013, 122, 3312-3312.	0.6	0
547	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	0.6	0
548	Whole Exome Sequencing Of Multiple Myeloma Reveals An Heterogeneous Clonal Architecture and Genomic Evolution. Blood, 2013, 122, 399-399.	0.6	0
549	A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2014, 32, TPS3117-TPS3117.	0.8	0
550	Important Prognostic Impact of Early Monocytes Recovery after Reduced Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. Blood, 2014, 124, 5923-5923.	0.6	0
551	Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 1834-1834.	0.6	0
552	Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation. Blood, 2015, 126, 3218-3218.	0.6	0
553	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. Blood, 2015, 126, 4339-4339.	0.6	0
554	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide. Blood, 2015, 126, 4245-4245.	0.6	0
555	Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Blood, 2015, 126, 4212-4212.	0.6	0
556	Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Elderly Multiple Myeloma (MM) Patients: A Prospective Multicenter Study. Blood, 2015, 126, 1989-1989.	0.6	0
557	Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment. Blood, 2015, 126, 4230-4230.	0.6	0
558	Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier. Blood, 2015, 126, 5519-5519.	0.6	0



#	ARTICLE	IF	CITATIONS
559	Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome. Blood, 2015, 126, 1947-1947.	0.6	0
560	Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of DLNO/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases. Blood, 2015, 126, 3122-3122.	0.6	0
561	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	0.6	0
562	The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing. Blood, 2016, 128, 236-236.	0.6	0
563	Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells. Blood, 2016, 128, 5866-5866.	0.6	0
564	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	0.6	0
565	Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM. Blood, 2016, 128, 3569-3569.	0.6	0
566	Responses Assigned Using Heavy+Light Chain Assessments Have Better Clinical Correlation with Outcome Than Those Using Current IMWG Criteria for Multiple Myeloma. Blood, 2016, 128, 3245-3245.	0.6	0
567	Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation " Results from the Tourmaline-MM1 Study. Blood, 2018, 132, 473-473.	0.6	0
568	No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide. Blood, 2018, 132, 4577-4577.	0.6	0
569	Influence of Donor Type (sibling vs matched-unrelated donor vs haplo-identical donor vs cord blood) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. Blood, 2018, 132, 3451-3451.	0.6	0
570	Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison. Blood, 2019, 134, 4739-4739.	0.6	0
571	Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study. Blood, 2019, 134, 3089-3089.	0.6	0
572	Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03). Blood, 2019, 134, 3190-3190.	0.6	0
573	Timing the Initiation of Multiple Myeloma. Blood, 2019, 134, 573-573.	0.6	0
574	The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 3055-3055.	0.6	0
575	Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allograft Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection. Blood, 2019, 134, 4528-4528.	0.6	0
576	Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allograft Using Purine Analogue/Busulfan-Based Conditioning Regimen. Blood, 2019, 134, 1985-1985.	0.6	0

#	ARTICLE	IF	CITATIONS
577	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. Blood, 2019, 134, 5771-5771.	0.6	0
578	Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients. Blood, 2021, 138, 3908-3908.	0.6	0
579	Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma. Blood, 2021, 138, 461-461.	0.6	0
580	Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. Blood, 2021, 138, 1655-1655.	0.6	0
581	Comparable Outcomes Among Adult Patients Allografted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study. Blood, 2021, 138, 4914-4914.	0.6	0
582	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. Blood, 2021, 138, 4095-4095.	0.6	0
583	Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease. Blood, 2021, 138, 3759-3759.	0.6	0
584	Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine. Blood, 2021, 138, 2895-2895.	0.6	0
585	Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases. Blood, 2020, 136, 2-3.	0.6	0
586	Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study. Blood, 2020, 136, 26-26.	0.6	0
587	Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study. Blood, 2020, 136, 15-17.	0.6	0
588	Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2022, 40, 8034-8034.	0.8	0